• Filing Date: 2021-03-31
  • Form Type: 10-K
  • Description: Annual report
v3.21.1
Business Combination (Details Narrative) - USD ($)
12 Months Ended
Oct. 16, 2020
Aug. 21, 2020
Mar. 03, 2020
Jul. 18, 2019
Dec. 31, 2020
Dec. 31, 2019
Aug. 18, 2020
Common stock, par value         $ 0.02 $ .02  
Debt instrument interest rate percentage         1.00%    
Debt principal amount         $ 844,000 $ 200,000  
Warrant exercise price per share         $ 0.029    
Shares issued price per share       $ 15.00      
Non-controlling interest         $ 3,430,000  
Issuance of common stock, net, shares       17,306  
Issuance of common stock, net         $ 20,196,000 $ 7,304,000  
Goodwill         26,862,000 2,454,000  
Deferred tax liabilities         3,499,000 $ 44,000  
Amortization of deferred charges            
Impact BioMedical, Inc. [Member]              
Common stock, par value   $ 0.02          
Shares issued during acquisition   483,334          
Shares issued price per share   $ 6.48          
Cost attributable to non-controlling interest   $ 51,000          
Deferred tax liabilities   5,234,000          
Impact BioMedical, Inc. [Member] | Goodwill [Member]              
Goodwill   25,093,000          
Impact BioMedical, Inc. [Member] | Development Technology [Member]              
Intangible assets acquired   22,260,000          
Impact BioMedical, Inc. [Member] | Patents [Member]              
Intangible assets acquired   $ 3,910,000          
Impact BioMedical, Inc. [Member] | Series A Convertible Preferred Stock [Member]              
Shares issued during acquisition 662,500 46,868          
Equity ownership percentage             19.99%
Maximum [Member] | Impact BioMedical, Inc. [Member]              
Equity ownership percentage   100.00%          
Minimum [Member] | Impact BioMedical, Inc. [Member]              
Equity ownership percentage   63.60%          
IPO [Member]              
Initial public offering percentage         50.00%    
IPO [Member] | Maximum [Member]              
Shares issued price per share         $ 10.00    
AMRE Asset Management Inc. [Member]              
Equity ownership percentage     52.50%        
Incurred cost         $ 900,000    
Non-controlling interest         $ 430,000    
American Medical Reit Inc. [Member]              
Equity ownership percentage     93.00%        
Singapore eDevelopment Limited [Member]              
Equity ownership percentage     82.00%        
Term Sheet [Member] | LiquidValue Asset Management Pte Ltd [Member]              
Equity ownership percentage     35.00%        
Term Sheet [Member] | AMRE Tennessee, LLC [Member]              
Equity ownership percentage     12.50%        
Term Sheet [Member] | American Medical Reit Inc. [Member]              
Debt instrument interest rate percentage     8.00%   8.00%    
Debt maturity date     Mar. 03, 2022        
Debt principal amount     $ 800,000        
Number of warrant to purchase shares of common stock     160,000        
Warrant exercise price per share     $ 5.00        
Warrant expiration date     Mar. 03, 2024        
Unsecured promissory note         $ 200,000    
Term Sheet [Member] | AMRE Asset Management Inc. [Member]              
Number of ordinary shares subscribed     5,250        
Common stock, par value     $ 0.01        
Value of ordinary shares subscribed     $ 53        
Equity ownership percentage     52.50%        
Term Sheet [Member] | AMRE Asset Management Inc. [Member] | LiquidValue Asset Management Pte Ltd [Member]              
Shares issued during acquisition     3,500        
Term Sheet [Member] | AMRE Asset Management Inc. [Member] | AMRE Tennessee, LLC [Member]              
Shares issued during acquisition     1,250        
Share Exchange Agreement [Member] | Impact BioMedical, Inc. [Member]              
Common stock, par value   $ 0.02          
Shares issued during acquisition   483,334          
Equity ownership percentage   100.00%          
Shares issued price per share   $ 6.48          
Share Exchange Agreement [Member] | Impact BioMedical, Inc. [Member] | Series A Convertible Preferred Stock [Member]              
Shares issued price per share   $ 1,000          
Issuance of common stock, net, shares   46,868          
Issuance of common stock, net   $ 46,868,000          
Consideration value   50,000,000          
Back-Solve [Member] | Impact BioMedical, Inc. [Member] | Series A Convertible Preferred Stock [Member]              
Issuance of common stock, net   35,187,000          
Consideration value   38,319,000          
General and administrative expenses   $ 295,000